Form 4: Adaptive Biotechnologies Executive Sells Shares to Cover Tax Obligations

Kyle Piskel, Principal Accounting Officer of Adaptive Biotechnologies, sold shares to cover tax withholding obligations related to vesting RSUs.

Summary

• On March 4, 2024, Kyle Piskel, the Principal Accounting Officer of Adaptive Biotechnologies, acquired 43,740 shares of common stock.
• These shares were acquired at a price of $0.
• On March 5, 2024, Piskel sold 7,727 shares of common stock at a price of $3.43 per share.
• The sale was to cover tax withholding obligations related to the vesting of Restricted Stock Units (RSUs).
• Following these transactions, Piskel beneficially owns 123,318 shares of Adaptive Biotechnologies common stock.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction (sell-to-cover) for tax obligations, which is neither particularly positive nor negative.

Management Comments

• The sale was mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a 'sell to cover' transaction and does not represent a discretionary trade by the Reporting Person.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, which can be informative for investors.

Stakeholder Impact

• The sale of shares by an officer could have a minor impact on shareholder sentiment, but is unlikely to be significant given the reason for the sale.

Key Dates